Donanemab targets beta-amyloid plaques in the brain, slowing cognitive decline by 4-7 months in early-stage Alzheimer's patients through 18-month treatment cycles. The drug costs approximately €40,000 and remains inaccessible to most patients; Portugal's health authority is evaluating potential NHS coverage while the UK's NICE rejected it as too expensive.
Observador
· May 16, 2026
· health
· 12 min de leitura
High
Apuração: Verificado
Donanemab slows Alzheimer's by 35%, but doctors split on cost-benefit
Two study participants died during clinical trials; approximately one-third of patients experienced brain swelling and some suffered cerebral hemorrhages, though most cases were reversible.
◉
Health & Medicine
2722 artigos relacionados
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% correspondência
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% correspondência
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% correspondência
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% correspondência
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% correspondência
Cobertura Relacionada
G1 · Aug 19
Macaé mobiliza 45 salas para atualizar vacinação de menores de 15 anos
Macaé lança campanha de atualização vacinal para menores de 15 anos em 45 pontos de saúde até 1º de setembro, com Dia D …
Agência FAPESP · Aug 19 Pesquisadores desenvolvem vacina inteligente contra chikungunya com vírus que se replica apenas uma vezCientistas da USP criaram uma vacina inovadora contra chikungunya usando vírus geneticamente modificado que se replica a…
G1 · Aug 19 Pastor belga do Senado é afastado após atacar veterinária que segue em estado graveVeterinária terceirizada sofre ataque grave de pastor belga malinois no Senado Federal em Brasília, com mordida no pesco…
Rádio Pampa · Aug 19 Heterossexuais são maioria entre pacientes que descobrem HIV em estágio avançadoEstudo em hospital de Porto Alegre revela que 84% dos pacientes diagnosticados com HIV em estágio avançado são heterosse…
Viés e Enquadramento
⚖
Article presents balanced coverage of Donanemab's efficacy against skepticism, though relies heavily on one specialist's optimistic framing while underrepresenting cost-benefit concerns.
Bias Direction
center-left
Confidence
MED
The article frames Donanemab as a promising innovation while acknowledging medical skepticism, but disproportionately features a single neurologist's enthusiastic endorsement ('revolutionary therapy') against vague references to broader medical community concerns. The opening emphasizes hope ('revolutionize patients' lives') before introducing counterarguments.
promete revolucionar a vida dos doentes (promises to revolutionize patients' lives)
terapêutica revolucionária (revolutionary therapy)
recebidos com algum ceticismo (received with some skepticism - downplays concerns)
asfixiam os neurónios (suffocate neurons - emotionally vivid language)
Patient voices or lived experiences with the treatment
Specific neurologists expressing skepticism (named sources for the 'split')
Pharmaceutical industry perspective on pricing justification
Health economics experts on cost-effectiveness analysis
NHS or public healthcare decision-makers explaining funding denial
Long-term outcome data beyond 18 months
Comparison with alternative treatments or standard care
Impacto Geopolítico
🌎
Donanemab approval in Portugal has minimal geopolitical implications; primarily a healthcare economics issue affecting EU pharmaceutical policy and NHS funding decisions.
Escalation Risk
low
Confidence
LOW
Portugal
European Union
United Kingdom
Western Europe
Pharmaceutical industry gains influence over healthcare policy; tension between private healthcare access (Portugal) and public system constraints (NHS); potential EU-wide regulatory harmonization discussions on expensive biologics.
Lente Econômica
📈
Donanemab, a new Alzheimer's treatment costing €40,000, slows disease progression by 35-40% but faces medical skepticism due to high costs, temporary effects, and lack of public funding coverage.
Market Signal
mixed
Confidence
HIGH
Pharmaceutical/Biotechnology
Healthcare Services
Private Healthcare
Public Health Systems
Insurance/Healthcare Finance
Patients with early-stage Alzheimer's gain access to disease-modifying treatment but face significant out-of-pocket costs (€40,000 for 18-month treatment). Unequal access likely between private and public healthcare users. Families must decide on treatment during early diagnosis when acceptance may be low.
Healthcare systems must evaluate cost-effectiveness and consider public funding decisions. Potential pressure for NHS/public system coverage negotiations. Regulatory bodies may require long-term efficacy data. Policy discussions needed on equitable access to expensive biologics and criteria for reimbursement in early-stage diseases.